Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
XF

NASDAQ · XFOR

X4 Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.77

Down-$0.13 (-4.48%)

Updated Oct 7, 2026, 2:22 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.21M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$2.73 – $4.83
Volume
642.47K
Avg. volume
894.59K

Price performance · XFOR

XFOR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

XFOR closed at $2.77 after 21 trading sessions, down 20.97% for the selected period.

Last close
$2.77
Period change
-20.97%
Period low
$2.77
Period high
$3.62
Daily close
View OHLC price history
XFOR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$2.90$2.90$2.70$2.77642.47K
Oct 5, 2026$2.88$2.935$2.73$2.90698.1K
Oct 2, 2026$2.86$2.86$2.745$2.83911.4K
Oct 1, 2026$2.89$2.95$2.82$2.83501.49K
Sep 30, 2026$2.93$2.935$2.845$2.901.76M
Sep 29, 2026$3.01$3.055$2.895$2.901.71M
Sep 28, 2026$2.996$3.04$2.81$3.015838.4K
Sep 25, 2026$2.98$3.0834$2.965$3.011.86M
Sep 24, 2026$3.10$3.10$2.955$3.00973.68K
Sep 23, 2026$3.41$3.42$3.035$3.112.31M
Sep 22, 2026$3.52$3.57$3.40$3.43923.76K
Sep 21, 2026$3.58$3.58$3.455$3.495444.36K
Sep 18, 2026$3.48$3.635$3.48$3.581.54M
Sep 17, 2026$3.56$3.585$3.41$3.50635.05K
Sep 16, 2026$3.63$3.65$3.355$3.51973.34K
Sep 15, 2026$3.60$3.64$3.31$3.622.08M
Sep 14, 2026$3.51$3.711$3.47$3.621.02M
Sep 11, 2026$3.44$3.55$3.24$3.501.25M
Sep 10, 2026$3.60$3.675$3.31$3.402.57M
Sep 9, 2026$3.50$3.67$3.45$3.601.4M
Sep 8, 2026$4.00$4.1254$3.19$3.5052.32M

Latest XFOR news

The latest Smart Investors Daily articles mentioning XFOR.

Stock researchCompany · Overview

XFOR research

Overview

Company profile and research snapshot.

Company profile

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.75
Implied upside
—
Analysts
—
XFOR recent ratings
DateFirmRatingTarget
Jul 10, 2026Wells FargoOverweight—
Jun 2, 2026Leerink PartnersOutperform—
Mar 9, 2026GuggenheimBuy—
Dec 5, 2025StifelBuy—
Nov 10, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of

Yahoo · Sep 9, 2026

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10, 2026 at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmaceuticals X4 Pharmac

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By